VANFLYTA

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Japan, Lithuania.

Active ingredients

The drug VANFLYTA contains one active pharmaceutical ingredient (API):

1	Quizartinib UNII WK7Q6ZIZ10 - QUIZARTINIB DIHYDROCHLORIDE
	Quizartinib is an inhibitor of the receptor tyrosine kinase FLT3. Quizartinib and its major metabolite AC886 competitively bind to the adenosine triphosphate (ATP) binding pocket of FLT3 with high affinity. Quizartinib and AC886 inhibit FLT3 kinase activity, preventing autophosphorylation of the receptor, thereby inhibiting further downstream FLT3 receptor signalling and blocking FLT3-ITDdependent cell proliferation.
	Read more about Quizartinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
VANFLYTA Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EX11		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors
Discover more medicines within L01EX11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3053135, 3053146, 3053157, 3053168, 3053179
FR	Base de données publique des médicaments	61354095, 69293541
IT	Agenzia del Farmaco	050967013, 050967025, 050967037, 050967049, 050967052
JP	医薬品医療機器総合機構	4291060F1021, 4291060F2028
LT	Valstybinė vaistų kontrolės tarnyba	1098046, 1098047, 1098048, 1098049, 1098050
US	FDA, National Drug Code	65597-504, 65597-511